<DOC>
	<DOCNO>NCT02355028</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 84 successive day topically administer LHA510 compare vehicle reduce number patient require intravitreal ( IVT ) anti-vascular endothelial growth factor ( VEGF ) therapy ( Lucentis® ) recurrence active choroidal neovascularization ( CNV ) .</brief_summary>
	<brief_title>LHA510 Proof-of-Concept Study Maintenance Therapy Patients With Wet Age-Related Macular Degeneration</brief_title>
	<detailed_description>The standard care recurrence active CNV IVT injection anti-VEGF agent . In study , recurrence CNV treat exclusively IVT Lucentis® . On Day -1 , patient receive IVT Lucentis® injection , randomize receive either topical LHA510 ophthalmic suspension vehicle 1:1 ratio .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Sign write informed consent form ; Wet AMD patient ; IVT antiVEGF therapy least 6 month maximum 7 year since 3rd load dose ; BCVA 50 letter ( approximate Snellen equivalent 20/100 ) good study eye ; Demonstrate ability administer eye drop ( patient caregiver ) ; CNV recently demonstrate high need frequent antiVEGF therapy sustain functional clear anatomical response study eye ; Other protocolspecified inclusion criterion may apply . Any active ocular periocular infection intraocular inflammation ; Current history macular retinal disease ( visually significant ) wet AMD study eye ; Current clinically significant vitreous hemorrhage history rhegmatogenous retinal detachment affect macula study eye ; History hypersensitivity study drug clinically relevant sensitivity fluorescein dye povidone iodine ; Women childbearing potential ; History medical condition , opinion Investigator , would preclude schedule study visit , completion study safe administration investigational product ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>LHA510</keyword>
	<keyword>PoC</keyword>
	<keyword>Age-related macular degeneration</keyword>
</DOC>